{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:42:36Z","timestamp":1794469356023,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T00:00:00Z","timestamp":1500422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12020-017-1360-z","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T04:35:09Z","timestamp":1500438909000},"page":"366-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review"],"prefix":"10.1007","volume":"57","author":[{"given":"David L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albertelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"1360_CR1","unstructured":"F.T. Bosman, World Health Organization, International Agency for Research on Cancer (ed.), in WHO Classification of Tumours of the Digestive System, 4th edn. (International Agency for Research on Cancer, Lyon, 2010)"},{"key":"1360_CR2","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"A. Rinke, H.-H. M\u00fcller, C. Schade-Brittinger, K.-J. Klose, P. Barth, M. Wied et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 27, 4656\u20134663 (2009)","journal-title":"J. Clin. Oncol."},{"key":"1360_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"M.E. Caplin, M. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedlackova et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224\u2013233 (2014)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501\u2013513 (2011)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514\u2013523 (2011)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"J.C. Yao, N. Fazio, S. Singh, R. Buzzoni, C. Carnaghi, E. Wolin et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968\u2013977 (2016)","journal-title":"Lancet"},{"key":"1360_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"M. Pavel, D. O\u2019Toole, F. Costa, J. Capdevila, D. Gross, R. Kianmanesh et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103, 172\u2013185 (2016)","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"1360_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000080742","volume":"80","author":"JC Reubi","year":"2004","unstructured":"J.C. Reubi, Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1), 51\u201356 (2004)","journal-title":"Neuroendocrinology"},{"key":"1360_CR10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.1994.tb17262.x","volume":"733","author":"JC Reubi","year":"1994","unstructured":"J.C. Reubi, J. Laissue, B. Waser, U. Horisberger, J.C. Schaer, Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann. N. Y. Acad. Sci. 733, 122\u2013137 (1994)","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1360_CR11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","volume":"315","author":"LK Kvols","year":"1986","unstructured":"L.K. Kvols, C.G. Moertel, M.J. O\u2019Connell, A.J. Schutt, J. Rubin, R.G. Hahn, Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 315, 663\u2013666 (1986)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"M.E. Caplin, M. Pavel, J.B. \u0106wik\u0142a, A.T. Phan, M. Raderer, E. Sedl\u00e1\u010dkov\u00e1 et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224\u2013233 (2014)","journal-title":"N. Engl. J. Med."},{"key":"1360_CR13","doi-asserted-by":"publisher","unstructured":"A. Giustina, G. Mazziotti, S. Cannav\u00f2, R. Castello, G. Arnaldi, G. Bugari, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. (2017). doi: 10.1210\/jc.2017-00142","DOI":"10.1210\/jc.2017-00142"},{"key":"1360_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi, S. Cannavo et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161, 331\u2013338 (2009)","journal-title":"Eur. J. Endocrinol."},{"key":"1360_CR15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"J. Rubin, J. Ajani, W. Schirmer, A.P. Venook, R. Bukowski, R. Pommier et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. 17, 600\u2013606 (1999)","journal-title":"J. Clin. Oncol."},{"key":"1360_CR16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1177\/0091270005277936","volume":"45","author":"B Astruc","year":"2005","unstructured":"B. Astruc, P. Marbach, H. Bouterfa, C. Denot, M. Safari, A. Vitaliti et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol. 45, 836\u2013844 (2005)","journal-title":"J. Clin. Pharmacol."},{"key":"1360_CR17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2169\/internalmedicine.33.100","volume":"33","author":"H Deguchi","year":"1994","unstructured":"H. Deguchi, K. Deguchi, T. Tsukada, S. Murashima, E. Iwasaki, M. Tsuda et al. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Intern. Med. 33, 100\u2013102 (1994)","journal-title":"Intern. Med."},{"issue":"Suppl 1","key":"1360_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000201402","volume":"57","author":"B Eriksson","year":"1996","unstructured":"B. Eriksson, E.T. Janson, N.D. Bax, M. Mignon, R. Morant, P. Opolon et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours. Digestion 57(Suppl 1), 77\u201380 (1996)","journal-title":"Digestion"},{"key":"1360_CR19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"J.R. Strosberg, A.B. Benson, L. Huynh, M.S. Duh, J. Goldman, V. Sahai et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 19, 930\u2013936 (2014)","journal-title":"Oncologist"},{"key":"1360_CR20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","volume":"4","author":"K Al-Efraij","year":"2015","unstructured":"K. Al-Efraij, M.A. Aljama, H.F. Kennecke, Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 4, 864\u2013870 (2015)","journal-title":"Cancer Med."},{"key":"1360_CR21","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"S Faiss","year":"2003","unstructured":"S. Faiss, U.-F. Pape, M. B\u00f6hmig, Y. D\u00f6rffel, U. Mansmann, W. Golder et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 21, 2689\u20132696 (2003)","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"1360_CR22","first-page":"73","volume":"103","author":"M Albertelli","year":"2016","unstructured":"M. Albertelli, D. Campana, A. Faggiano, F. Spada, R. Baldelli, P. Ferolla et al. Safety of high doses lanreotide treatment in patients with progressive neuroendocrine tumors: results from a prospective phase II trial. Neuroendocrinology 103(Suppl 1), 73 (2016)","journal-title":"Neuroendocrinology"},{"key":"1360_CR23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s12325-011-0062-9","volume":"28","author":"WH Ludlam","year":"2011","unstructured":"W.H. Ludlam, L. Anthony, Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv. Ther. 28, 825\u2013841 (2011)","journal-title":"Adv. Ther."},{"key":"1360_CR24","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3748\/wjg.v21.i6.1945","volume":"21","author":"MS Broder","year":"2015","unstructured":"M.S. Broder, D. Beenhouwer, J.R. Strosberg, M.P. Neary, D. Cherepanov, Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J. Gastroenterol. 21, 1945\u20131955 (2015)","journal-title":"World J. Gastroenterol."},{"key":"1360_CR25","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"J.A. Sterne, M.A. Hern\u00e1n, B.C. Reeves, J. Savovi\u0107, N.D. Berkman, M. Viswanathan et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919 (2016)","journal-title":"BMJ"},{"key":"1360_CR26","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"E Wolin","year":"2015","unstructured":"E. Wolin, B. Jarzab, B. Eriksson, T. Walter, C. Toumpanakis, M.A. Morse et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des. Dev. Ther. 9, 5075\u20135086 (2015)","journal-title":"Drug Des. Dev. Ther."},{"key":"1360_CR27","first-page":"326","volume":"35","author":"P Ferolla","year":"2012","unstructured":"P. Ferolla, A. Faggiano, F. Grimaldi, D. Ferone, G. Scarpelli, V. Ramundo et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J. Endocrinol. Invest. 35, 326\u2013331 (2012)","journal-title":"J. Endocrinol. Invest."},{"key":"1360_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","volume":"151","author":"SV Welin","year":"2004","unstructured":"S.V. Welin, E.T. Janson, A. Sundin, M. Stridsberg, E. Lavenius, D. Granberg et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol. 151, 107\u2013112 (2004)","journal-title":"Eur. J. Endocrinol."},{"key":"1360_CR29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","volume":"60","author":"S Faiss","year":"1999","unstructured":"S. Faiss, U. R\u00e4th, U. Mansmann, D. Caird, N. Clemens, E.O. Riecken et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60, 469\u2013476 (1999)","journal-title":"Digestion"},{"key":"1360_CR30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","volume":"8","author":"B Eriksson","year":"1997","unstructured":"B. Eriksson, J. Renstrup, H. Imam, K. Oberg, High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann. Oncol. 8, 1041\u20131044 (1997)","journal-title":"Ann. Oncol."},{"key":"1360_CR31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/02841869709001323","volume":"36","author":"H Imam","year":"1997","unstructured":"H. Imam, B. Eriksson, A. Lukinius, E.T. Janson, P.G. Lindgren, E. Wilander et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol. 36, 607\u2013614 (1997)","journal-title":"Acta Oncol."},{"key":"1360_CR32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","volume":"38","author":"R Arnold","year":"1996","unstructured":"R. Arnold, M.E. Trautmann, W. Creutzfeldt, R. Benning, M. Benning, C. Neuhaus et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38, 430\u2013438 (1996)","journal-title":"Gut"},{"key":"1360_CR33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","volume":"77","author":"M Bartolomeo di","year":"1996","unstructured":"M. di Bartolomeo, E. Bajetta, R. Buzzoni, L. Mariani, C. Carnaghi, L. Somma et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group. Cancer 77, 402\u2013408 (1996)","journal-title":"Cancer"},{"key":"1360_CR34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/02841869309083915","volume":"32","author":"L Anthony","year":"1993","unstructured":"L. Anthony, D. Johnson, K. Hande, M. Shaff, S. Winn, M. Krozely et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 32, 217\u2013223 (1993)","journal-title":"Acta Oncol."},{"key":"1360_CR35","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1634\/theoncologist.2015-0381","volume":"21","author":"C Shen","year":"2016","unstructured":"C. Shen, Y. Xu, A. Dasari, Y.-C.T. Shih, J.C. Yao, Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. Oncologist 21, 308\u2013313 (2016)","journal-title":"Oncologist"},{"key":"1360_CR36","doi-asserted-by":"publisher","unstructured":"R. Modica, V. Ramundo, F. Marciello, V. Marotta, G. Pizza, A.C. Carratu, et al. High-dose treatment with somatostatin analogues in neuroendocrine tumours. Endocr. Abstr. (2015). doi: 10.1530\/endoabs.37.EP1132","DOI":"10.1530\/endoabs.37.EP1132"},{"key":"1360_CR37","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.18632\/oncotarget.6686","volume":"7","author":"A Faggiano","year":"2016","unstructured":"A. Faggiano, A.C. Carrat\u00f9, E. Guadagno, S. Tafuto, F. Tatangelo, F. Riccardi et al. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 7, 5538\u20135547 (2016)","journal-title":"Oncotarget"},{"key":"1360_CR38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","volume":"40","author":"L Anthony","year":"2011","unstructured":"L. Anthony, A.I. Vinik, Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 40, 987\u2013994 (2011)","journal-title":"Pancreas"},{"key":"1360_CR39","first-page":"4127","volume":"29","author":"MK Chadha","year":"2009","unstructured":"M.K. Chadha, J. Lombardo, T. Mashtare, G.E. Wilding, A. Litwin, C. Raczyk et al. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 29, 4127\u20134130 (2009)","journal-title":"Anticancer Res."},{"key":"1360_CR40","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/ERC-11-0287","volume":"19","author":"A Koumarianou","year":"2012","unstructured":"A. Koumarianou, S. Antoniou, G. Kanakis, N. Economopoulos, D. Rontogianni, A. Ntavatzikos et al. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr. Relat. Cancer 19, L1\u2013L4 (2012)","journal-title":"Endocr. Relat. Cancer"},{"key":"1360_CR41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","volume":"29","author":"MH Kulke","year":"2011","unstructured":"M.H. Kulke, L.L. Siu, J.E. Tepper, G. Fisher, D. Jaffe, D.G. Haller et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the national cancer institute neuroendocrine tumor clinical trials planning meeting. J. Clin. Oncol. 29, 934\u2013943 (2011)","journal-title":"J. Clin. Oncol."},{"key":"1360_CR42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MPA.0b013e31816907ab","volume":"37","author":"EA Woltering","year":"2008","unstructured":"E.A. Woltering, V.A. Salvo, T.M. O\u2019Dorisio, J. Lyons, G. Li, Y. Zhou et al. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas 37, 94\u2013100 (2008)","journal-title":"Pancreas"},{"issue":"Suppl","key":"1360_CR43","doi-asserted-by":"crossref","first-page":"Abstr e15126","DOI":"10.1200\/jco.2013.31.15_suppl.e15126","volume":"31","author":"AT Phan","year":"2013","unstructured":"A.T. Phan, E.M. Wolin, J.A. Chan, J. Huang, M. Hudson, G. Hughes et al. Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 31(Suppl), Abstr e15126 (2013)","journal-title":"J. Clin. Oncol."},{"key":"1360_CR44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/MJT.0b013e31824c3eb4","volume":"21","author":"M Shenouda","year":"2014","unstructured":"M. Shenouda, M. Maldonado, Y. Wang, E. Bouillaud, M. Hudson, D. Nesheiwat et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am. J. Ther. 21, 164\u2013173 (2014)","journal-title":"Am. J. Ther."},{"key":"1360_CR45","doi-asserted-by":"publisher","unstructured":"S.K. Abell, J. Teng, A. Dowling, M.S. Hofman, R.J. MacIsaac, N. Sachithanandan, Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinol. Diab. Metab. Case Rep. (2015). doi: 10.1530\/EDM-14-0097","DOI":"10.1530\/EDM-14-0097"},{"key":"1360_CR46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1517\/14740338.2010.510130","volume":"9","author":"MW Saif","year":"2010","unstructured":"M.W. Saif, H. Larson, K. Kaley, W. Shaib, Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin. Drug Saf. 9, 867\u2013873 (2010)","journal-title":"Expert Opin. Drug Saf."},{"key":"1360_CR47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1634\/theoncologist.2011-0458","volume":"17","author":"L Sid\u00e9ris","year":"2012","unstructured":"L. Sid\u00e9ris, P. Dub\u00e9, A. Rinke, Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 17, 747\u2013755 (2012)","journal-title":"Oncologist"},{"key":"1360_CR48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12630-012-9879-1","volume":"60","author":"N Seymour","year":"2013","unstructured":"N. Seymour, S.C. Sawh, Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review. Can. J. Anaesthesiol. 60, 492\u2013499 (2013)","journal-title":"Can. J. Anaesthesiol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1360-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1360-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T22:15:27Z","timestamp":1602540927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1360-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1360-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}